250 related articles for article (PubMed ID: 25145549)
1. Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.
Berrocal A; Cabañas L; Espinosa E; Fernández-de-Misa R; Martín-Algarra S; Martínez-Cedres JC; Ríos-Buceta L; Rodríguez-Peralto JL
Adv Ther; 2014 Sep; 31(9):945-60. PubMed ID: 25145549
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib in melanoma.
Shaw HM; Nathan PD
Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
5. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
Schaefer T; Satzger I; Gutzmer R
Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
[TBL] [Abstract][Full Text] [Related]
6. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
Dean E; Lorigan P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
[TBL] [Abstract][Full Text] [Related]
8. [BRAF mutation: a novel approach in targeted melanoma therapy].
Arenbergerová M; Puzanov I
Klin Onkol; 2012; 25(5):323-8. PubMed ID: 23102192
[TBL] [Abstract][Full Text] [Related]
9. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
10. [Melanoma- finally good news].
Wicki A; Arnold AW; Itin PH; Zippelius A
Praxis (Bern 1994); 2013 May; 102(11):667-70. PubMed ID: 23692905
[TBL] [Abstract][Full Text] [Related]
11. Novel therapies in melanoma.
Scheier B; Amaria R; Lewis K; Gonzalez R
Immunotherapy; 2011 Dec; 3(12):1461-9. PubMed ID: 22091682
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib and ipilimumab: new agents for metastatic melanoma.
Banaszynski M; Kolesar JM
Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456
[TBL] [Abstract][Full Text] [Related]
13. Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma.
Buckley B; Pierce B
JAAPA; 2018 May; 31(5):24-26. PubMed ID: 29698368
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
Lang N; Weisser A; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
[No Abstract] [Full Text] [Related]
15. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
Heakal Y; Kester M; Savage S
Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept, ipilimumab, and vemurafenib.
Hussar DA; Au AY
J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387
[No Abstract] [Full Text] [Related]
17. [Major therapeutic advances in the treatment of metastatic melanoma].
Mateus C; Robert C
Bull Cancer; 2012 Jun; 99(6):619-25. PubMed ID: 22652330
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
19. [Translational research and diagnostics of melanoma].
Rüschoff J; Kleinschmidt M; Middel P
Pathologe; 2012 Nov; 33 Suppl 2():291-5. PubMed ID: 22968732
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
